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Background: Cut-off values for change in left ventricular end-diastolic volume (LVEDV) 43 
and LV end-systolic volume (LVESV) by cardiovascular magnetic resonance (CMR) 44 
following ST-segment elevation myocardial infarction (STEMI) have recently been proposed 45 
and 4 patterns of LV remodeling were described. We aimed to assess their long-term 46 
prognostic significance. 47 
Methods: A prospective cohort of unselected STEMI patients with paired acute and 6-month 48 
CMR, with the 5-year composite endpoint of all-cause death and hospitalization for heart 49 
failure was included. The prognosis of the following groups [Group 1: reverse LV 50 
remodeling (≥12% decrease in LVESV); Group 2: no LV remodeling (changes in LVEDV 51 
and LVESV <12%); Group 3: adverse LV remodeling with compensation (≥12% increase in 52 
LVEDV only); and Group 4: adverse LV remodeling (≥12% increase in both LVESV and 53 
LVEDV)] was compared. 54 
Results: 285 patients were included with a median follow-up was 5.8 years. The composite 55 
endpoint occurred in 9.5% in Group 1, 12.3% in Group 2, 7.1% in Group 3 and 24.2% in 56 
Group 4. Group 4 had significantly higher cumulative event rates of the composite endpoint 57 
(log-rank test p=0.03) with the other 3 groups showing similar cumulative event rates (log-58 
rank test p=0.51). Cox proportional hazard for Group 2 [HR 1.3 (95% CI 0.6-3.1), p=0.53] 59 
and Group 3 [HR 0.6 (95% CI 0.2-2.3), p=0.49] were not significantly different but was 60 
significantly higher in Group 4 [HR 3.0 (95% CI (1.2-7.1), p=0.015] when compared to 61 
Group 1. 62 
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Conclusions: Patients with STEMI developing adverse LV remodeling at 6 months, defined 63 
as ≥12% increase in both LVESV and LVEDV by CMR, was associated with worse long-64 
term clinical outcomes than those with adverse LV remodeling with compensation, reverse 65 
LV remodeling and no LV remodeling, with the latter 3 groups having similar outcomes in a 66 
cohort of stable reperfused STEMI patients.  67 
Clinical Trial Registration Information: BHF MR-MI study, 68 
https://clinicaltrials.gov/ct2/show/NCT02072850 69 
 70 
Key words: ST-segment elevation myocardial infarction, magnetic resonance imaging, left 71 




Short Commentary 74 
In a prospective cohort of 285 STEMI patients with paired acute and 6-month CMR, patients 75 
with adverse LV remodeling defined as ≥12% increase in both LVESV and LVEDV was 76 
associated with worse 5-year clinical outcomes in terms of all-cause death and hospitalization 77 
for heart failure than those with adverse LV remodeling with compensation (≥12% increase 78 
in LVEDV only) , reverse LV remodeling (≥12% decrease in LVESV) and no LV 79 
remodeling (changes in LVEDV and LVESV <12%), with the latter 3 groups having similar 80 
outcomes. Firstly, this definition for adverse LV remodeling of ≥12% increase in both 81 
LVESV and LVEDV at 6 months could be used as a screening tool to identify high-risk 82 
patients who could benefit from therapies such as mineralocorticoid receptor antagonist or 83 
neprilysin inhibitor/ angiotensin receptor blocker combination therapy to improve long term 84 
outcomes. Secondly, ≥12% increase in both LVESV and LVEDV could also be used as a 85 
new surrogate endpoint at 6 months for proof-of-concept studies targeting post-infarct LV 86 
remodeling. Our findings need to be validated in a larger cohort of patients as well as in those 87 







 Despite reperfusion of the infarct-related artery by primary percutaneous coronary 92 
intervention (PPCI), adverse left ventricular (LV) remodeling occurs in a significant 93 
proportion of patients with ST-elevation myocardial infarction (STEMI)1. This is associated 94 
with the development of heart failure2 and poor clinical outcomes3. Conversely, reverse LV 95 
remodeling post-STEMI has been shown to be associated with good clinical outcomes 4.  96 
Cardiovascular magnetic resonance (CMR) is established as the gold standard 97 
modality not only for quantifying myocardial infarct (MI) size5, 6 and microvascular 98 
obstruction (MVO)7, but also for measuring LV volumes and LV ejection fraction (LVEF)5, 8. 99 
As a result, CMR is increasingly being used to assess surrogate clinical end-points following 100 
STEMI in cardioprotection studies.9 By echocardiography, adverse LV remodeling following 101 
STEMI has been conventionally defined as ≥20% increase in LV end-diastolic volume 102 
(LVEDV) from baseline10, 11 and reverse LV remodeling has been defined as ≥10% decrease 103 
in LV end-systolic volume (LVESV)12.  104 
Recently, cut-off values for the change in LVEDV and LVESV by CMR have been 105 
proposed based on a minimal detectable change of 12%. Four patterns of post-STEMI LV 106 
remodeling were defined: Group 1: reverse LV remodeling (≥12% decrease in LVESV); 107 
Group 2: no LV remodeling (changes in LVEDV and LVESV within <12%); Group 3: 108 
adverse LV remodeling with compensation (≥12% increase in LVEDV only); and Group 4: 109 
adverse LV remodeling (≥12% increase in both LVEDV and LVESV)13. However, these 110 
were not linked to clinical outcomes.  111 
Therefore, we aimed to determine the prognostic value of the above 4 groups of LV 112 
remodeling defined by CMR at 6 months in a large cohort of STEMI survivors 14-16. We 113 
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hypothesized that among survivors of STEMI, different patterns of LV remodeling at 6 114 
months by CMR would carry different prognosis; Group 1 would have the best long-term 115 





 The data that support the findings of this study are available from the corresponding 119 
author upon reasonable request. 120 
The study design has been reported (BHF MR-MI: NCT02072850) 14, 16-18 and is 121 
detailed in the Supplementary Methods. In brief, this was a prospective study with 122 
consecutive eligible patients recruited from a single centre between May 2011 and November 123 
2012 following informed consent. The eligibility criteria included an indication for PPCI or 124 
thrombolysis for STEMI and exclusion criteria were standard contraindications to CMR or 125 
inability to tolerate a CMR scan (e.g. claustrophobia, inability to lie flat due to 126 
decompensated heart failure or mechanical complications, hemodynamic instability due to 127 
ventricular arrhythmias or cardiogenic shock). The study received ethics approval (reference 128 
10-S0703-28) and was registered on clinicaltrials.gov (NCT02072850). Only patients with 129 
paired CMR data on LV volumes at baseline and at 6 months follow-up were included in this 130 
study. 131 
CMR image analysis 132 
 Cardiac magnetic resonance imaging (CMR) analysis was performed on a Siemens 133 
workstation. LV volumes and LV ejection fraction were assessed using computer assisted 134 
planimetry (Syngo MR®, Siemens Healthcare, Erlangen, Germany) on the short-axis cine 135 
images with minimal manual adjustment when required and the LVEDV, LVESV, LV mass 136 
and LVEF were quantified by following standard recommendations5. Percentage change 137 
(%Δ) in LVEDV and LVESV were calculated as the difference between the follow-up 138 
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parameters and the corresponding baseline parameters and expressed as a percentage of the 139 
baseline parameters. 140 
Health outcomes 141 
 Adverse health outcomes that are implicated in the pathophysiology and natural 142 
history of STEMI were pre-specified. The primary composite outcome all-cause death and 143 
hospitalization for heart failure (HHF) at 5 years following discharge from hospital, 144 
independently adjudicated as per the event adjudication charter in the online appendix.  145 
Statistical analysis 146 
 Statistical analysis was performed using SPSS version 25 (IBM Corporation, Illinois, 147 
US). Continuous data was expressed as mean ± standard deviation (SD) or median 148 
(interquartile range) and categorical data was reported as frequencies and percentages. 149 
Groups were compared using one-way analysis of variance/ Kruskal-Wallis or Fisher’s exact 150 
test where appropriate. Cumulative hazard curves were used to assess survival at 5 years per 151 
group of LV remodeling and were compared using log-rank test. The primary analysis for the 152 
cumulative incidence of all-cause death and HHF at 5 years per group was performed using 153 
Cox proportional hazard (with censoring of data to the date of occurrence of the primary 154 
endpoint, lost to follow-up, withdrawal from the study or at 5 years) and the hazard ratios 155 
(HRs) were computed with 95% confidence interval.  Adjusted HRs were also calculated 156 
after accounting for acute MI size, MVO and LVEF on the initial scan, the latter three factors 157 
being known prognostic CMR markers19 and also accounting for baseline Global Registry of 158 
Acute Coronary Events (GRACE) score. All statistical tests were two-tailed, and P<0.05 was 159 





 Of 391 patients referred for PPCI or urgent PCI following thrombolysis, 324 163 
underwent the acute CMR at 2.2±1.9 days and 300 patients returned for the 6-month follow-164 
up scan. 293 patients had matching LV volumes data and were included in this study (Figure 165 
1). The median follow-up duration was 2120 days (5.8 years) with a range of 233 to 2456 166 
days.  167 
Patient characteristics 168 
 The majority of patients (46.8%) had reverse LV remodeling (Group 1) followed by 169 
24.9% with no LV remodeling (Group 2). 14.3% with adverse LV remodeling and 170 
compensation (Group 3) and 11.3% with adverse LV remodeling (Group 4). There were 8 171 
patients (2.7%) with ≥12% increase in LVESV only who did not fall in any of the above 4 172 
groups (Figure 2).  173 
The characteristics of these 285 patients are shown in Table 1. The mean age was 59±11 174 
years and 74% were male. There were no differences in baseline characteristics including 175 
baseline comorbidities, drugs on discharge, pain onset-to-balloon time, angiographic 176 
characteristics and ST-segment resolution among the 4 groups.   177 
Acute and follow-up CMR findings 178 
 The CMR findings are summarized in Table 2. Acute MI size was significantly 179 
different among the 4 groups (p<0.001). Group 4 had significantly larger MI size than Group 180 
1 (p=0.001) but there was no statistically significant difference when compared to Group 2 181 
(p=0.66) or Group 3 (p=1.0). The proportion of patients with MVO was lowest in Group 1 182 
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(38%) but similar in Groups 2 to 4 (MVO: 59%, 62% and 61%, respectively). However, 183 
among those with MVO, the extent of MVO was largest in Group 4 (11.7% LV mass). Acute 184 
LVESV was significantly lower in Group 2 (62ml) when compared to Group 1 (72ml, 185 
p=0.036). Acute LVEF was significantly higher in Group 2 (59%) when compared to Group 186 
1 (54%, p=0.007) and Group 3 (51%, P<0.001). All other pairwise comparison did not reach 187 
statistical significance. Acute LVEDV and LV mass were similar among the 4 groups 188 
(P=0.31 and P=0.24, respectively) (Table 2). 189 
 At 6 months, those in Group 1 and Group 2 had significantly smaller chronic MI size 190 
(9% LV mass and 12% LV mass, respectively) than Group 4 (19% LV mass, P<0.001 and 191 
P=0.044, respectively) (Table 2). Group 4 had the lowest LVEF at follow-up (52%) when 192 
compared to Groups 1 to 3 (P<0.001 for pairwise comparison). However, LVEDV and 193 
LVESV were similar between Groups 3 and 4 (P=1.0 and P=0.24, respectively), but Groups 1 194 
and 2 had significantly smaller LVEDV and LVESV than Group 4 (LVEDV: P<0.001 and 195 
P=0.004; LVESV: P<0.001 and P=0.001, respectively) (Table 2). Follow-up LV mass were 196 
similar among the 4 groups (P=0.19) (Table 2). 197 
A subset of patients had CMR data on intramyocardial hemorrhage (IMH) on the acute scan 198 
(218) and residual iron at follow-up (n = 243). The incidence of IMH was lowest in Group 1 199 
(24%) but those in Groups 2 to 4 had similar incidences (53%, 55% and 54%, respectively). 200 
Residual iron was significantly higher in Group 4 (40%), similar between Groups 2 (32%) 201 
and 3 (28%), and lowest in Group 1 (10%), P<0.001 for trend 202 
LV remodeling at 6 months and clinical outcomes 203 
The composite endpoint of all-cause death and HHF occurred in 9.5% in Group 1, 12.3% in 204 
Group 2, 7.1% in Group 3 and 24.2% in Group 4. The breakdown of the individual endpoints 205 
in each group is provided in Table 3. Cumulative hazard plot analysis showed that those in 206 
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Group 4 had significantly higher cumulative event rates of the composite endpoint (log-rank 207 
test p=0.03) when compared to the 3 other groups, with the latter 3 groups showing similar 208 
cumulative event rates (log-rank test P=0.51) (Figure 3). Using Group 1 as reference, the Cox 209 
proportional hazard for Groups 2 [HR 1.3 (95% CI 0.6-3.1), P=0.53] and 3 [HR 0.6 (95% CI 210 
0.2-2.3), P=0.49] were not significantly different but significantly higher for those in Groups 211 
4 [HR 3.0 (95% CI (1.2-7.1), P=0.015]. These findings remained consistent after adjusting 212 
for acute MI size, MVO and initial LVEF with Group 4 having the worse prognosis [adjusted 213 
HR 2.5 (95% 1.0-6.3), P=0.044], whereas those in Groups 2 [adjusted HR 1.3 (95% 0.5-3.0), 214 
P=0.61] and 3 [adjusted HR 0.5 (95% 0.1-1.8), P=0.28] had similar prognosis to Group 1. 215 
Similar findings were obtained after adjusting for GRACE score with Group 4 having the 216 
worse prognosis [adjusted HR 2.7 (95% 1.0-7.4), P=0.049], whereas those in Groups 2 217 
[adjusted HR 1.7 (95% 0.7-4.2), P=0.2] and 3 [adjusted HR 0.8 (95% 0.2-2.7), P=0.67] had 218 






 We have shown that in a cohort of unselected STEMI patients with paired acute and 222 
6-month CMR data, those with adverse LV remodeling, defined as the combination of a 223 
≥12% increase in both LVEDV and LVESV from baseline (Group 4), have significantly 224 
worse prognosis in terms of the composite endpoint of all-cause mortality and HHF after a 225 
median follow-up of 5.8 years, when compared to patients with any of the 3 other patterns of 226 
LV remodeling. Of note, those with an isolated ≥12% increase in LVEDV only (Group 3) 227 
had a similar prognosis to those with reverse LV remodeling (Group 1) or no LV remodeling 228 
(Group 2). Our findings extend and validate prior work in a derivation cohort.13  229 
 Our findings are relevant for clinical practice and therapeutic trials. We have provided 230 
evidence that adverse LV remodeling following STEMI should be defined as a ≥12% 231 
increase in both LVEDV and LVESV and this approach clearly identified a high-risk group 232 
of patients at 6 months. The implications are two-fold: firstly, this definition could be used as 233 
a screening tool to identify high-risk patients and they could be targeted with further potential 234 
therapies such as mineralocorticoid receptor antagonist or neprilysin inhibitor/ angiotensin 235 
receptor blocker combination therapy; secondly, this definition could be used as a new 236 
surrogate endpoint at 6 months for proof-of-concept studies targeting post-infarct LV 237 
remodeling.  238 
 LV remodeling is usually assessed using echocardiography10,11,12 but has also been 239 
assessed using single-photon computed tomography (SPECT) and CMR20. Computed 240 
tomography (CT) is another modality to assess serial LV volumes21. Although assessment of 241 
LV volumes by SPECT and CT are highly reproducible, they utilize ionized radiation. 242 
Recently, the use of CMR to assess LV remodeling has gathered momentum. Reindl et al22 243 
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recently proposed a cut-off of ≥10% increase in LVEDV at 4 months to define adverse LV 244 
remodeling by CMR based on a study of 224 patients. However their follow-up time was 245 
only 2 years and their composite endpoints included stroke, non-fatal myocardial re-246 
infarction together with all-cause mortality and HHF, the former 2 endpoints being not 247 
directly related to the development of adverse LV remodeling22. The number of events was 248 
small (n=13), which make their analysis prone to statistical fragility. Furthermore, the 249 
cumulative hazard curves for health outcomes indicates that events occurring prior to the 4-250 
month CMR may not have been excluded22. Most recently, Rodriguez-Palomares et al23 in a 251 
larger cohort of 374 patients, showed that the optimal definition for adverse LV remodeling 252 
that predicted outcomes after a mean follow-up of 6 years was a combination of a 15% 253 
increase in LVEDV and a 3% reduction in LVEF at 6 months. LVEDV was used to estimate 254 
LVEF therefore given this association (and inverse correlation) it is not surprising that those 255 
with both and increase in LVEDV and a decrease in LVEF had worse prognosis. However, 256 
those with a 15% increase in LVEDV alone or a 3% decrease in LVEF alone also showed 257 
some prognostic significance when compared to those with neither of those changes and 258 
therefore their definition for adverse LV remodeling does not identify all the high risk 259 
patients23.  260 
 Reverse LV remodeling is prognostic in chronic heart failure, including in patients 261 
undergoing cardiac resynchronization therapy24, 25. In the STEMI setting, Funaro et al showed 262 
that reverse LV remodeling occurred in 39% of their study population and was prognostic 4. 263 
However, there were only 110 patients in their study and the follow-up period was 2 years 264 
only 4. They only compared their patients into two groups, without differentiating those who 265 
developed adverse LV remodeling to those with no LV remodeling 4. Their events included 9 266 
HHF, 3 cardiac deaths and 4 non-fatal MI, the latter unlikely to be directly linked to the 267 
development of adverse LV remodeling 4. Our study, included a larger number of patients 268 
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and had a follow-up duration period of 5-year with clinical outcomes assessed blind to the 269 
baseline data. We suggest our findings provide substantive evidence for this combinatory 270 
approach to prognostication. 271 
Limitations 272 
 We included a cohort of relatively low-risk STEMI survivors who could tolerate a 273 
CMR scan acutely and at 6 months. We included all-cause mortality rather than cardiac 274 
mortality as not all causes of deaths could be adjudicated with adequate certainty. We used 275 
CMR to assess LV remodeling. The number of patients in each group was relatively small 276 
and the number of events were also low at only 33 (11.6%). Future research should assess 277 
external validity in other post-MI populations assessed with different imaging methods.   278 
Conclusion 279 
 In a cohort of unselected, stable reperfused STEMI patients who could tolerate a 280 
CMR scan, those with a 12% increase in both LVEDV and LVESV (adverse LV remodeling) 281 
by CMR at 6 months was associated with worse clinical outcomes after a median follow-up 282 
of 5 years than those with a 12% increase in LVEDV alone (adverse LV remodeling with 283 
compensation), those with a 12% reduction in LVESV (reverse LV remodeling) and those 284 
with no changes to their LVESV and LVESV (no LV remodeling).  Therefore, a 12% 285 
increase in both LVEDV and LVESV at 6 months by CMR could be considered as a 286 
definition for adverse LV remodeling in the setting of STEMI. Reverse LV remodeling did 287 
not carry prognostic significance in our study. The findings could be relevant for risk 288 
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Figure Titles and Legends 386 
Figure 1: Flow diagram of the patients’ screening and selection process 387 
Of 391 patients screened, 324 underwent CMR at 2.2±1.9 days and 300 patients returned for 388 
a second scan at 6-months. Matching LV volumes data were available for 293 patients and 389 
they were included in this study. 390 
Figure 2. Distribution of the patients in the 4 main groups according to their change in 391 
LVEDV and LVESV from baseline 392 
This graph shows the distribution of the percentage change in LVESV against LVESV of the 393 
whole cohort of patients in this study and colour coded according to groups. A minority of 394 
patients (n=8) had an increase in LVESV only and were not classified.  395 
Figure 3. Cumulative hazard curves of the cumulative event rates of the 4 groups of LV 396 
remodeling 397 
The cumulative event rates of the composite endpoint of all-cause death and HHF for the 4 398 
groups are shown in this cumulative hazard plot with their corresponding HRs. Those in 399 
Group 4 had had significantly higher cumulative event rates of the composite endpoint (log-400 
rank test P<0.001) when compared to the 3 other groups. 401 
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Age 59±11 60±11 58±12 57±12 59±11 0.45 
Male Gender 216 (74%) 100 (73%) 49 (67%) 32 (76%) 28 (84%) 0.28 
Diabetes Mellitus 33 (11%) 16 (12%) 7 (10%) 3 (7%) 5 (15%) 0.70 
Hypertension 95 (32%) 45 (33%) 21 (29%) 12 (29%) 14 (43%) 0.52 
Dyslipidaemia 84 (29%) 43 (31%) 21 (29%) 9 (21%) 9 (27%) 0.66 
Smoking 176 (60%) 80 (58%) 46 (63%) 25 (60%) 21 (64%) 090 
Previous MI 20 (7%) 10 (7%) 5 (7%) 0 (0%) 5 (15.2%) 0.09 











































































































































































































3 vessel disease 41 (14%) 19 (14%) 9 (12%) 6 (15%) 7 (23%) 
MI: myocardial infarction; GRACE: Global Registry of Acute Coronary Events; ACEI: angiotensin converting 403 
enzyme inhibitor; MRA: mineralocorticoid receptor antagonist; SBP: systolic blood pressure; DBP: diastolic 404 
blood pressure; IRA: infarct related artery; LMS: left main stem; LAD: left anterior descending artery; Cx: 405 
circumflex artery; RCA: right coronary artery; PCI: percutaneous coronary intervention; TIMI: thrombolysis in 406 


















MI size/ % LV mass 16 (7-27%) 13 (4-21) 15 (7-25) 25 (13-32) 29 (10-36) <0.001 
MVO/ % 146 (50%) 52 (38%) 43 (59%) 26 (62%) 20 (61%) 0.003 











IMH (n=218) 87/218 (40%) 24/101 (24%) 32/60 (53%) 17/31 (55%) 14/26 (54%) <0.001 
LVEF/% 55±10 54±8 59±10 51 ±10 55±12 <0.001 
LVEDV/ ml 150 (127-175) 154 (133-179) 145 (123-169) 155 (115-170) 145 (120-173) 0.31 
LVESV/ ml 66 (49-86) 72 (54-87) 62 (45-76) 73 (57-93) 64 (43-98) 0.036 
LV mass/ g 133 (105-152) 134 (106-153) 128 (101-143) 142 (99-161) 133 (114-166) 0.24 
 
6-months CMR 
MI size/ % LV mass 11 (4-19) 9 (3-14) 12 (4-19) 19 (10-24) 19 (7-32) <0.001 
Residual iron (n=243) 52/243 (21%) 11/116 (10%) 21/66 (32%) 10/36 (28%) 10/25 (40%) <0.001 
LVEF/% 62±9 66±7 61±8 60±9 52±11 <0.001 
LVEDV/ ml 154 (127-186) 146 (120-168) 154 (127-171) 182 (134-203) 185 (146-219) <0.001 
 
 24 
LVESV/ ml 57 (40-74) 47 (37-64) 58 (43-72) 74 (55-89) 79 (61-118) <0.001 
LV mass/ g 116 (96-137) 116 (95-135) 116 (95-132) 119 (96-141) 127 (111-143) 0.19 
 
%Δ in LV parameters from baseline 
%Δ MI size -29 (-46--6) -33 (-48--6) -29 (-47--4) -27 (-45--15) -21(-45-0) 0.73 
%ΔLVEDV 3 (-5-13) -5 (-13-2) 4 (-1-7) 17 (14-21) 26 (17-33) <0.001 
%ΔLVESV -26 (-12-4) -27 (-38--19) -4 (-9-4) -4 (-13-5) 31 (18-53) <0.001 
%ΔLVEF 10 (3-18) 16 (11-23) 4 (0-7) 15 (9-21) -4 (-19-4) <0.001 
%ΔLV mass -10 (-17--2) -11 (-19--4) -10 (-16--2) -9(-20--3) -7(-21--4) 0.51 
MI: myocardial infarction; LV: left ventricular; MVO: microvascular obstruction; IMH: 410 
intramyocardial hemorrhage; LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-411 




Table 3: Pre-specified clinical outcomes at 5-years. 414 









Composite of all-cause 
death and HHF 
13 (9.5%) 9 (12.3%) 3 (7.1%) 8 (24.2%) 33 (11.6%) 
HHF 2 (1.5%) 0 (0%) 0 (0%) 3 (9.1%) 5 (1.8%) 
All-cause death 11 (8.0%) 9 (12.3%) 3 (7.1%) 5 (15.2%) 28 (9.8%) 
HHF: hospitalization for heart failure 415 
 416 
